Top Dow Dividend Stocks To Buy For 2014

On Thursday, Union Pacific (NYSE: UNP  ) will release its latest quarterly results. The key to making smart investment decisions on stocks reporting earnings is to anticipate how they'll do before they announce results, leaving you fully prepared to respond quickly to whatever inevitable surprises arise. That way, you'll be less likely to make an uninformed knee-jerk reaction to news that turns out to be exactly the wrong move.

Union Pacific has benefited from the cost advantage that railroads have during periods of high energy prices, but the devastation in the commodities markets recently has had a negative impact on shipping volume. Nevertheless, the railroad giant has managed to turn to alternative revenue sources. Let's take an early look at what's been happening with Union Pacific over the past quarter and what we're likely to see in its quarterly report.

Stats on Union Pacific

Analyst EPS Estimate

Top 10 Supermarket Stocks To Own For 2015: Mazda Motor Corp (MZDAY.PK)

Mazda Motor Corporation is a Japan-based company engaged in the manufacture and distribution of automobiles and automobile parts. The Company provides mini vans, compact vehicles, sports cars, sport-utility vehicles, station wagons, sedans, light cars, commercial vehicles, welfare vehicles and special edition automobiles, as well as automobile accessories, including car navigation systems, automobile audio systems, side monitors, rear seat monitors, electronic toll collection (ETC) in-vehicle equipment, security products, driving support products, bulbs, pet carriers and child seats, among others. As of March 31, 2013, the Company had 56 consolidated subsidiaries and 15 associated companies. Advisors' Opinion:

• [By Elliott Gue]

  This so-called One Ford initiative involved the US$2.3 billion sale of Jaguar and Land Rover to Tata Motors (TTM) and the US$1.6 billion divestment of Volvo to Geely Automobile Holdings (GELYF.PK). After selling the majority of its stake in Mazda Motor Corp (MZDAY.PK) and discontinuing Mercury, Ford Motor Company's portfolio consists of its eponymous mass-market brand and the higher-end Lincoln.

Top Dow Dividend Stocks To Buy For 2014: Westmoreland Coal Company(WLB)

Westmoreland Coal Company operates as an energy company in the United States. The company, through its subsidiaries, engages in the production and sale of sub-bituminous coal and lignite to electricity generating plants; and the ownership of power plants in North Carolina. It owns 5 surface coal mines in Montana, North Dakota, and Texas; and 2 coal-fired power generating units with a capacity of approximately 230 megawatts in Weldon, North Carolina. As of December 31, 2010, Westmoreland Coal Company had estimated proven and probable coal reserves of 389.9 million tons. The company was founded in 1854 and is headquartered in Englewood, Colorado.

Advisors' Opinion:

• [By John Udovich]

  Obama�� war on coal has claimed another victim as James River Coal Company (NASDAQ: JRCC) files for Chapter 11, but coal stocks Westmoreland Coal Company (NASDAQ: WLB), Alliance Resource Partners, L.P. (NASDAQ: ARLP) and Hallador Energy Co (NASDAQ: HNRG) have still managed to put in a decent performance for investors���despite the industry headwinds coming from the White House. Just consider this: By 2025, 300 of America�� coal plants will close due to EPA policies for a total of 44,000 megawatts of generating capacity in 33 states to be taken off line. Moreover, Democrats have been putting up roadblocks to stop coal exports���one potential industry bright spot as the US�has the largest coal repository in the world.

• [By Jake L'Ecuyer]

  Leading and Lagging Sectors
  In trading on Tuesday, energy shares were relative leaders, up on the day by about 1.41 percent. Meanwhile, top gainers in the sector included Stone Energy (NYSE: SGY), up 9 percent, and Westmoreland Coal Co (NYSE: WLB), up 7.8 percent. Industrials services shares gained by just 0.02 percent in Tuesday's trading.

Top Dow Dividend Stocks To Buy For 2014: TomTom NV (OEM)

TomTom NV is a Netherlands-based supplier of location and navigation products and services. The Company�� structure consists of four customer facing business units, namely Consumer, Automotive, Business Solutions and Licensing. The first three business units provide targeted solutions for the Company�� customers, including private consumers, car manufacturers and fleet owners. Licensing sells its content and services to multiple customer groups including portable navigation devices (PNDs) and wireless companies, governments and enterprises. The Company�� business units embed 11 product units, such as digital maps, traffic intelligence, navigation software, PNDs, automotive systems, fleet management services (FMS), smart phone applications, sports watches, points of interest, location based services (LBS) and speedcam intelligence. As of December 31, 2011, the Company was active in 35 countries. In July 2013, it acquired Coordina (Gestion Electronica Logistica, S.L.). Advisors' Opinion:

• [By victorselva]

  In a macro view, revenues in the electronic equipment and instrument sub-industry will remain strong due to the rise in equipment and instrument manufacturers. Distributors, electronic manufacturing service (EMS) companies and original equipment manufacturers (OEM) are going to increase orders as the economy improves in the future. With this promising outlook, let's take a look at Gabelli麓s last trade and try to explain to investors the reasons of this appealing investment opportunity.

• [By ICRAOnline]

  In the previous three-month period (fourth quarter), revenue fell 4% year over year to $1.65 billion mainly on account of 33.7% drop in original equipment manufacturer (OEM) revenues and 0.8% decline in branded revenues. Product revenues dropped 8.4%, which was partially compensated by 8% improvement in service revenues.

Top Dow Dividend Stocks To Buy For 2014: Neogenomics Inc (NEO)

NeoGenomics, Inc. (NeoGenomics) operates a network of cancer-focused testing laboratories. The Company offers testing services, including Cytogenetics testing, which is the study of normal and abnormal chromosomes and their relationship to disease; fluorescence in-situ hybridization (FISH) testing, which is a branch of cancer genetics that focuses on detecting and locating the presence or absence of specific deoxyribonucleic acid (DNA) sequences and genes on chromosomes; flow cytometry testing, which is a way to measure the characteristics of cell populations; immunohistochemistry (IHC) testing, this is the process of identifying cell proteins in a tissue section utilizing the principle of antibodies binding specifically to antigens, and molecular testing, which is a cancer diagnostic tool focusing on the analysis of DNA and ribonucleic acid (RNA), as well as the structure and function of genes at a molecular level.

The cancer testing services, that the Company offers to community-based pathologists are designed to be a natural extension of, and complementary to, the services that they perform within their own practices. In areas where the Company does not provide services to community-based pathology practices, it may directly serve oncology, dermatology, urology and other clinician practices that prefer to have a direct relationship with a laboratory for cancer-related genetic and molecular testing services. NeoGenomics services these types of clients with a global service offering where it performs both the technical and professional components of the tests ordered.

The Company offers tech-only flow cytometry and immunohistochemistry testing services. These types of testing services generally allow the professional interpretation component of a test to be billed separately from the technical component. Its NeoFISH, NeoFLOW and other tech-only service offerings allow properly trained and credentialed community-based pathologists to extend their own practices by performing ! professional interpretations services.

The Company's tech-only services are designed to give pathologists the option to choose, on a case by case basis, whether they want to order just the technical information and images relating to a specific test so they can perform the professional interpretation, or order global services and receive a test report, which includes a NeoGenomics Pathologist�� interpretation of the test results.

The Company also offers a set of global services to meet the needs of those clients who are not credentialed and trained in interpreting genetic tests and who are looking for specialists to interpret the testing results for them. In its global service offerings, its lab performs the technical component of the tests and its doctor of medicine (M.D.s) and doctor of philosophy (Ph.D) s to provide the interpretation services. Its genetic pathology solutions (GPS) report summarizes all relevant case data from its global services on one summary report.

The Company competes with General Electric Healthcare Services and Novartis, A.G.

Advisors' Opinion:

• [By John Udovich]

  One way or the other, Merrimack Pharmaceuticals Inc (NASDAQ: MACK), Covidien plc (NYSE: COV), NeoGenomics, Inc (NASDAQ: NEO) and�CollabRx Inc (NASDAQ: CLRX) are targeting Barrett's Esophagus�or�esophageal cancer�(the former often leads to the latter) ��a form of cancer that may not be on the top of your list of cancers but is nevertheless on the rise. Approximately 3 million Americans suffer from Barrett's Esophagus, �a condition that�develops as a result of chronic injury from gastroesophageal reflux disease (GERD) where the�normal esophageal lining is replaced with abnormal cells (known as Barrett�� tissue), putting patients at greater risk of developing cancer of the esophagus. And although less than 1% of these patients develop cancer each year, esophageal carcinoma is frequently not detected until later stages, at which point therapy options are limited, extremely invasive, and often ineffective.�This means that�early detection is important�along with�regular surveillance is recommended.�

Top Dow Dividend Stocks To Buy For 2014: Anheuser-Busch InBev (BUD)

Anheuser-Busch InBev SA/NV, incorporated on August 2, 1977, is a brewing company. The Company produces, markets, distributes and sells a balanced portfolio of approximately 200 beer brands. These include global flagship brands Budweiser, Stella Artois and Beck��; multi-country brands, such as Leffe and Hoegaarden, and many local champions, such as Bud Light, Skol, Brahma, Quilmes, Michelob, Harbin, Sedrin, Klinskoye, Sibirskaya Korona, Chernigivske and Jupiler. The Company also produces and distributes soft drinks, particularly in Latin America. The Company operates in seven segments: North America, Latin America North, Latin America South, Western Europe, Central & Eastern Europe, Asia Pacific and Global Export & Holding Companies. On October 20, 2010, Companhia de Bebidas das Americas-AmBev (AmBev) and Cerveceria Regional S.A. closed a transaction pursuant, to which they combined their businesses in Venezuela, with Regional owning an 85% interest and AmBev owning the remaining 15% in the new company. On February 28, 2011, the Company closed a transaction with Dalian Daxue Group Co., Ltd and Kirin (China) Investment Co., Ltd to acquire a 100% equity interest in Liaoning Dalian Daxue Brewery Co., Ltd. The Company�� beer portfolio is divided into global, multi-country and local brands. Beer can be differentiated into the categories, such as premium brands; mainstream or core brands, and value, discount or sub-premium brands. The Company also has a presence in the soft drink market in Latin America through its subsidiary AmBev and in the United States through Anheuser-Busch Companies, Inc. (Anheuser-Busch). Soft drinks include both carbonated soft and non-carbonated soft drinks. Its soft drinks business includes both its own production and agreements with PepsiCo related to bottling and distribution. The brands that are distributed under these agreements are Pepsi, 7UP and Gatorade. AmBev has long-term agreements with PepsiCo whereby AmBev has the exclusive right to bottle, sell and distribute certain brands of PepsiCo�� portfolio of carbonated soft drinks in Brazil. In the United States, Anheuser-Busch also produces non-alcoholic malt beverage products, including O��oul�� and O��oul�� Amber, energy drinks and related products. In the United States, its indirect subsidiary, Metal Container Corporation, manufactures beverage cans at eight plants and beverage can lids at three plants for sale to its Anheuser-Busch beer operations and United States soft drink customers. Anheuser-Busch also owns a recycling business, which buys and sells used beverage containers and recycles aluminum and plastic containers; a manufacturer of crown liner materials for sale to its North American beer operations, and a glass manufacturing plant which manufactures glass bottles for use by its North American beer operations. Advisors' Opinion:

• [By Dan Caplinger]

  2. Missouri
  The traditional home of Anheuser-Busch InBev (NYSE: BUD  ) , Missouri charges just $0.06 per gallon in beer excise taxes. Again, the key presence of a major brewer is probably behind the state's decision to minimize taxes on beer. Somewhat surprisingly, beer consumption isn't all that high, with the 31.1 gallons per year of beer that the average person drinks barely enough to put Missouri into the top 20.

• [By Alyce Lomax]

  Still, it's a sticky area. When you think of volume and sales growth some of the best, most "loyal" customers for companies like Molson Coors (NYSE: TAP  ) , Boston Beer (NYSE: SAM  ) , Anheuser-Busch (NYSE: BUD  ) , and Brown-Forman (NYSE: BF-B  ) are going to be some of their most addicted and most troubled ones. If enough people curbed their intake -- obviously an important part of many people getting well -- the industry would have a real problem to contend with. Like tobacco, a whole lot of quitters shrinks the market.

• [By gurujx]

  Anheuser-Busch Inbev SA (BUD) Reached the 52-Week High of $105.40

  Anheuser-Busch Inbev SA has a market cap of $169.73 billion; its shares were traded at around $105.60 with a P/E ratio of 13.30 and P/S ratio of 9.50. The dividend yield of Anheuser-Busch Inbev SA stocks is 2.40%. Anheuser-Busch Inbev SA had an annual average earnings growth of 9.50% over the past 10 years.

• [By Sean Williams]

  Many mass-produced beer companies, such as Anheuser-Busch InBev (NYSE: BUD  ) and Molson Coors (NYSE: TAP  ) , have struggled in domestic markets since the recession as consumers have opted for even cheaper beers, or have decided to pay a premium for craft beers and made the move toward Boston Beer or other small craft brewers. In 2010, for example, sales of Budweiser dropped 7.3% while Miller High Life saw sales dip 4%. This same year saw Sam Adams tack on a gain of 1.7%! This doesn't even take into account the fact that domestic competition has spiked, with the number of brewers in the U.S. jumping from just 89 in the late 1970s to more than 2,400 by the end of 2012, according to the Brewers Association.

Top Dow Dividend Stocks To Buy For 2014: NovaBay Pharmaceuticals Inc. (NBY)

NovaBay Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in the development of various product candidates for the therapeutic needs of the anti-infective market. Its products include Aganocide compounds comprising NVC-422 that are synthetic molecules for the treatment of impetigo and adenoviral conjunctivitis, as well as for reducing the incidence of urinary catheter blockage and encrustation, and the associated urinary tract infections. The company is also involved in developing NeutroPhase, a solution for cleansing and debriding wounds. It has collaboration and license agreement with Galderma S.A. to develop and commercialize its Aganocide compounds, which covers acne, impetigo, and other dermatological conditions. The company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in February 2007. NovaBay Pharmaceuticals, Inc. was incorporated in 2000 and is based in Emeryville, California.

Advisors' Opinion:

• [By CRWE]

  NovaBay(r) Pharmaceuticals, Inc. (Amex:NBY), a clinical-stage biotechnology company developing its first-in-class, anti-infective Aganocide(r) compounds for the local non-systemic treatment and prevention of infections, reported that Tom Paulson, Chief Financial Officer, will present at the Rodman & Renshaw 14th Annual Healthcare Conference held September 9-11, 2012, in New York, NY.